Challenges of pharmacovigilance automation

October 15, 2021

Challenges of pharmacovigilance automation

The development of information technology is significantly ahead of the development of regulatory and other legislation. Despite the obvious benefits of introducing new technologies in electronic systems for pharmacovigilance, it is necessary to consider the difficulties that a company will face:

Validation and audits completion

  • New approaches need to be developed to ensure quality, pass user acceptance testing, provide evidence of the validated status of the electronic system during an audit, and that the company has full control over its electronic system, regardless of the level and method of automation used in it.

Personal data management

  • It is necessary that legislation on the protection of personal data (for example, GDPR in Europe) is strictly observed in relation to new systems

Personnel training, possible changes in the organizational structure of the company

  • The introduction of new technologies will require new competencies from the staff of the pharmacovigilance and quality assurance departments
  • The introduction of new technologies may require company restructuring and additional resources

When we developed the Pharmacovigilance module, we considered all possible difficulties and propose the following solutions:

  • Flex Databases system is validated, we provide clients with a package of validation documents to prove the status of the system, as well as assistance in passing user acceptance testing
  • We strictly comply with the legislation on personal data and comply with all international and local regulations
  • For a painless and effective start of work with our system, during the implementation of the module, Flex Databases product specialists conduct detailed training on working with the system for employees of the client company

The entire pharmacovigilance process, from receiving the message to reporting and identifying safety signals, can be automated, thereby limiting the amount of human intervention that will still be required for exception handling, quality assurance, and analysis. Usage of automation is costly, but it will reduce data-processing costs, eliminate the potential for human error, and improve data quality and accuracy.

If you are interested in pharmacovigilance automation and want to learn more about the Flex Databases system – write to us at bd@flexdatabases.com or send a request for a demo through the form in the header of the page.

Blog

April 28, 2026
Flex Databases x SOLTI taking the stage at #OCT2026

We’re heading to Barcelona for OCT 2026. And this time, we’re bringing a real story with us! Our colleague Evgenia will be speaking alongside Jaume Costa from SOLTI, our dear client and long-term partner, about the question many teams still struggle with: Who should own your eClinical systems: sponsor or CRO? Stream B: AI & […]

April 15, 2026
TMF Blinding: Removing the Complexity of Managing Blinded Studies

Blinded studies are critical for maintaining the integrity of clinical trials. But while the concept is straightforward, the operational reality is often anything but. For many clinical teams, managing blinding means dealing with: This creates a constant burden: Even with strict processes in place, a single misconfiguration can compromise the entire study. TMF Blinding in […]

April 2, 2026
CTMS for CRO Financial Management: Managing Clinical Trial Budgets and Investigator Payments

Financial management is critical because CROs must ensure that clinical trials remain within budget while generating expected revenue. Without proper financial oversight, organizations may experience delayed payments, incorrect invoicing, or reduced project profitability. A CTMS helps CROs maintain financial control and improve operational efficiency. Financial management is one of the most complex operational areas for […]

April 1, 2026
Risk-Based Monitoring (RBM) in Clinical Trials: A Comprehensive Guide to Modern Oversight

For decades, the clinical research industry operated under a manual, labor-intensive oversight model. The gold standard was 100% Source Data Verification (SDV) – a process where Clinical Research Associates (CRAs) traveled to sites to painstakingly cross-reference every data point in a Case Report Form against medical records. However, as trials have become more data-saturated and […]

Contact us

Get in touch to discuss compliance, implementation, demos, pricing

We are here for all of your questions! Tell us more about yourself and we will organize a tailored live demo to show how you can power up your clinical trials processes with Flex Databases.